Cutting-Edge Approaches to Obesity Management: The Latest Pharmacological Options.
Endocrinol Metab Clin North Am · 2025
Last updated 2026-05-28Seven FDA-approved medications are available for obesity management, including liraglutide (3.0 mg), semaglutide (2.4 mg), and tirzepatide. These drugs are intended for long-term use alongside diet, exercise, and behavioral changes. The article reviews their approval data, how they work, dosing, side effects, and other key details.
AI summary of the abstract below.
| Journal | Endocrinol Metab Clin North Am, 2025 |
|---|---|
| Citations | 5 |
| Relative citation ratio | 1.78 |
| Molecules | — |
| Conditions studied | Obesity |
Abstract
Successful treatment of obesity requires a multidisciplinary approach including dietary strategy, physical activity, and behavioral modification. The seven FDA-approved anti-obesity medications are phentermine, orlistat, phentermine/topiramate ER, naltrexone SR/bupropion SR, liraglutide 3.0 mg, semaglutide 2.4 mg, and tirzepatide. Obesity is a chronic disease and these medications should be prescribed with the intention of long-term use. In this article, we summarize data from phase 3 clinical trials which led to drug approval, and we review the clinical indications, mechanism of action, dosing/administration, side effects, drug interactions and contraindications for each medication.
Verbatim abstract via PubMed 39919879 ↗